Neumora Therapeutics, Inc..
NMRA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Neumora Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for central nervous system (CNS) disorders and neurodegenerative diseases. The company's pipeline includes various clinical and preclinical programs targeting a range ...Show More
Better Health for All
-20
Neumora Therapeutics is a biopharmaceutical company focused on discovering and developing novel therapeutics for central nervous system disorders and neurodegenerative diseases, with a mission to redefine neuroscience drug development for improved patient outcomes. Its pipeline includes programs targeting Major Depressive Disorder, Alzheimer's Disease agitation, Schizophrenia, Obesity/Parkinson's Disease, and ALS.
1
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score in patients with Alzheimer's Disease agitation, with a placebo-adjusted change of -2.6 and -2.1 at Weeks 6 and 8 respectively, and a Cohen’s d effect size range of 0.20 – 0.23.
2
In a pre-specified elevated anxiety population, it showed a -7.6 and -5.6 placebo-adjusted change with a Cohen’s d effect size range of 0.51 – 0.64.
3
However, a clinical depression drug (Navacaprant) had Phase 3 study results that failed to show a statistically significant result.
4
NMRA-511 demonstrated a favorable tolerability and safety profile with low treatment discontinuations due to treatment emergent adverse events (TEAEs) at 2.5%.
5
The most common adverse effects were typically mild to moderate.
6
A proposed class action lawsuit alleges the company concealed critical issues with its Phase 2 trial, including potentially too few participants and an improper gender ratio, leading to sullied data.
7
The company's stock declined nearly 89% since its market debut.
8
Neumora states its goal is to obtain regulatory approval for its medications to serve patients and that information about its trials is available at clinicaltrials.gov.
9
The company does not accept requests for expanded access to investigational products until safety, tolerability, and effectiveness are confirmed.
10
Amgen made a $100 million equity investment into Neumora as part of a strategic R&D collaboration.
11
Fair Money & Economic Opportunity
0
No evidence available to assess Neumora Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data was found in the provided articles for any of the 'Fair Pay & Worker Respect' KPIs. Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage percentage for the workforce was not explicitly stated.
1
While some articles mentioned executive compensation, employee headcount changes, or eligibility for benefits, these did not provide the precise metrics required by the rubric's quantitative thresholds for scoring.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles regarding Neumora Therapeutics, Inc.'s performance on fair trade and ethical sourcing metrics. This includes fair-trade certification share, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
Honest & Fair Business
-20
Neumora Therapeutics, Inc. has a confidential and anonymous financial concern hotline and web form for reporting complaints regarding accounting, internal accounting controls, or auditing matters, or other ethics or compliance issues.
1
A 14 to 16-digit code is provided to track the status of messages submitted through the hotline.
2
The Board has determined that all directors, other than one or two named individuals (Mr. Berns in Article 3, and Messrs. Berns and Gosebruch in Article 4), qualify as 'independent' directors in accordance with Nasdaq listing requirements.
3
The company has adopted a Code of Business Conduct and Ethics that applies to its officers, directors, and employees.
4
Ernst & Young LLP has audited the company's financial statements for each fiscal year since December 31, 2019,
5
and the Audit Committee oversees their work.
6
Kind to Animals
-60
The company's preclinical studies involve animal testing, including rabbits, non-human primates, and rats.
1
Preclinical data showed convulsions in rabbits dosed with NMRA-266, leading to an FDA clinical hold on its phase 1 trial.
2
Similarly, nonclinical safety pharmacology studies of NMRA-511 indicated dose-limiting toxicities, including tremor and convulsions in non-human primates, which resulted in a partial clinical hold.
3
The company states that certain laws and regulations require it to test product candidates on animals before initiating human clinical trials.
4
The articles do not provide specific annual animal testing volumes, but the nature of the findings (convulsions in rabbits and non-human primates) suggests significant animal use in preclinical development.
No War, No Weapons
0
No evidence available to assess Neumora Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No sustainability data is available for Neumora Therapeutics (NMRA.US) across any of the specified Planet-Friendly Business metrics.
1
The provided articles explicitly state a complete absence of quantitative data, regulatory actions, violations, fines, certifications, awards, or comparisons to industry benchmarks related to environmental performance.
2
Respect for Cultures & Communities
0
The provided articles do not contain any specific, concrete data points or factual evidence to assess Neumora Therapeutics, Inc. against the 'Respect for Cultures & Communities' ethical value. Information regarding formal partnerships with community groups, reinvestment in local development, cultural appropriation incidents, impact assessment protocols, local employment, grievance mechanisms, FPIC processes, community governance, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training is not available.
1
Safe & Smart Tech
0
The provided articles discuss Neumora Therapeutics' business model, funding, clinical trials, and the application of data science and AI/ML in its drug discovery process, including a 'Precision Toolbox' with proprietary algorithms. While the company acknowledges the importance of data security and the potential for breaches, the articles do not contain specific, concrete data points or verifiable facts regarding its actual data protection practices, cybersecurity investments, privacy certifications, employee security training, encryption implementation, AI ethics governance, algorithmic audit practices, algorithmic transparency, unauthorized data use incidents, user data control, authentication security, vulnerability management, bug bounty programs, privacy by design integration, security testing coverage, data minimization practices, regulatory compliance with privacy regulations, algorithmic harm remediation, or digital rights advocacy.
1
Therefore, no KPIs under the 'Safe & Smart Tech' value can be scored based on the evidence provided.
Zero Waste & Sustainable Products
0
No specific evidence for Neumora Therapeutics, Inc. (NMRA.US) regarding 'Zero Waste & Sustainable Products' or its associated KPIs was found in the provided articles. Article 5, from the company's investor relations site, explicitly states that it contains no information related to these metrics.
1
All other articles discuss the pharmaceutical industry in general or initiatives by other specific companies, not NMRA.US.